Clinical impact of laboratory error on therapeutic drug monitoring of once-daily tobramycin in cystic fibrosis: Case series

William A Prescott and Michelle A Mancuso

Abstract
Once-daily dosing intravenous tobramycin is commonly used to treat cystic fibrosis pulmonary exacerbations. Clinicians often utilize historical therapeutic drug monitoring data to individualize the dose among patients who have been treated with tobramycin previously. This case series involves three patients with cystic fibrosis who had supra-therapeutic tobramycin levels despite use of a once-daily dosing that produced therapeutic drug levels during a previous hospital admission, raising questions about the validity of these levels. Investigation into several potential sources of error led to the discovery of an analyzer error in the laboratory. Once the laboratory’s tobramycin analyzer was recalibrated, the reported levels were comparable to historical levels. This case series emphasizes the clinical importance of critically analyzing reported levels, and specifically, the importance of utilizing past therapeutic drug monitoring data, if available, for all patients treated with intravenous tobramycin. If a patient was therapeutic on a similar dose of tobramycin during a previous admission, a dose adjustment may not be necessary, and clinicians should consider repeating levels while pursuing alternative explanations for the discrepant serum levels.

Keywords
Cystic fibrosis, aminoglycoside, tobramycin, therapeutic drug monitoring, laboratory error

Date received: 20 September 2013; accepted: 23 December 2013

Introduction
Intravenous (IV) tobramycin is utilized in the treatment of cystic fibrosis (CF) pulmonary exacerbations in the setting of Pseudomonas aeruginosa colonization.1 Tobramycin is often administered as a once-daily dosing (ODD), with an empiric dose of 10 mg/kg/day being most common.2 Many clinicians utilize historical therapeutic drug monitoring data to individualize the dose among patients who have been treated with tobramycin previously.2 To ensure safe and effective treatment with ODD, the dose is adjusted upward or downward to maintain serum concentrations within a specified target range if indicated. We present a case series involving three patients with CF who were each found to have supra-therapeutic tobramycin levels despite use of an ODD dose that produced therapeutic drug levels during a previous hospitalization. Upon investigation, it was determined that an unnoticed and unreported laboratory error involving the tobramycin analyzer occurred. The purpose of this case series is to illustrate the clinical importance of considering multiple factors when assessing drug levels during ODD of tobramycin in CF.

Case series
Each patient was admitted for treatment of a CF pulmonary exacerbation and received ODD tobramycin at a weight-based dose that produced therapeutic concentrations during the most recent hospitalization (Table 1). The actual body weight for each patient changed less than 3% between the time of the most recent and current hospitalizations. Throughout the current hospitalization, each patient had normal renal function and hydration status as based on blood urea nitrogen (BUN) and serum creatinine (SCr) values and urine output. Home treatment with inhaled tobramycin was discontinued upon admission in each patient. Serum samples for tobramycin analysis were drawn approximately 2 and 10 h post start of
Table 1. Tobramycin therapeutic drug monitoring for previous and current hospitalization.

| Case/hospitalization | Date       | Dose (mg) | Dose (mg/kg) | First collected level (mg/L)a | Second collected level (mg/L)b | Calculated peak (mg/L)c,d | Calculated 18-h level (mg/L)c,d | Calculated trough (mg/L)d,e | AUC (mg·h/L)d |
|----------------------|------------|-----------|--------------|-------------------------------|-------------------------------|---------------------------|------------------------------|-----------------------------|----------------|
| Case 1               |            |           |              |                               |                               |                           |                              |                             |                |
| Previous admissionf  | 05/16/XX  | 670       | 9.9          | 21.4                          | 1.5                           | 24.8                      | 0.16                         | 0.027                      | 103.3          |
| Current, day 2       | 10/18/XX  | 660       | 10           | 27.8                          | 2.7                           | 38.4                      | 0.24                         | 0.04                       | 158.8          |
| Current, day 3       | 10/19/XX  | 660       | 10           | 41.7                          | 2.4f                          | 57.9h                      | 0.15h                        | 0.018h                      | 209.2h         |
| Current, day 4       | 10/20/XX  | 660       | 10           | 20.6d                         | 2.4f                          | 27.0                      | 0.28                         | 0.055                      | 212.8          |
| Case 2               |            |           |              |                               |                               |                           |                              |                             |                |
| Previous admissionf  | 04/06/XX  | 560       | 10           | 21.3                          | 1.3                           | 25.8                      | 0.1                          | 0.013                      | 98.3           |
| Current, day 1       | 10/18/XX  | 560       | 9.9          | 26.4                          | n/a                           | n/a                       | n/a                          | n/a                        | n/a            |
| Current, day 2       | 10/19/XX  | 560       | 9.9          | 33.1                          | 1.8f                          | 47.6h                      | 0.1h                         | 0.011h                      | 167.2h         |
| Current, day 3       | 10/20/XX  | 560       | 9.9          | 23.2d                         | 1.3f                          | 33.3                      | 0.07                         | 0.008                      | 117.7          |
| Current, day 4       | 10/21/XX  | 480       | 8.5          | 18.9d                         | 1.2f                          | 26.6                      | 0.08                         | 0.01                       | 98.3           |
| Case 3               |            |           |              |                               |                               |                           |                              |                             |                |
| Previous admissionf  | 04/11/XX  | 450       | 10.2         | 16.0                          | 0.8                           | 24.3                      | 0.04                         | 0.004                      | 83.2           |
| Previous admissionf  | 04/12/XX  | 550       | 12.5         | 15.7                          | 1.5                           | 26.9                      | 0.15                         | 0.024                      | 109.3          |
| Current, day 1       | 10/19/XX  | 450       | 10           | 28.1                          | 1.0f                          | 43.5h                      | 0.04h                        | 0.003h                      | 137.0h         |
| Current, day 2       | 10/20/XX  | 450       | 10           | 14.3e                         | 1.3e                          | 19.3                      | 0.12                         | 0.02                       | 79.6           |
| Current, day 3       | 10/21/XX  | 550       | 12.2         | 29.4e                         | 1.4e                          | 42.0                      | 0.06                         | 0.006                      | 141.5          |
| Current, day 4       | 10/22/XX  | 500       | 11.1         | 19.4d                         | 1.4f                          | 26.3                      | 0.1                          | 0.014                      | 101.0          |

AUC: area under the concentration time curve; n/a: not available.

a Drawn 2 h post start of infusion (precise dose and sampling times were documented in the chart per hospital policy and were all within 10 min of scheduled time).

b Drawn 10 h post start of infusion (precise dose and sampling times were documented in the chart per hospital policy and were all within 10 min of scheduled time).

c Calculated peak corresponds to the level 0.5 h post 0.5-h infusion.

d Calculated trough corresponds to the level 24 h post-dose.

e Previous and current hospitalizations occurred during the same calendar year.

f Level drawn following re-calibration of tobramycin analyzer.

The peak serum concentration was used to determine whether the dose was therapeutic, while the trough and AUC were used to determine whether the dose was safe. Because ODD may be monitored through collection of a single aminoglycoside serum concentration (e.g. an 18-h post-dose level), our CF center’s policy is to utilize patient-specific pharmacokinetic parameters using a validated online dosing calculator designed specifically for the institution’s CF center (http://www.pharmacistassist.com/). All samples were collected via peripheral venipuncture and were analyzed in the hospital’s laboratory using a Beckman Coulter UniCel DxC 800 Chemistry Analyzer (Beckman Coulter, Brea, CA, USA).

Case 1

Patient 1 was a 17-year-old 66-kg female admitted on 10/17. She presented with increased productive cough, green sputum, some hemoptysis, decreased pulmonary function tests (PFTs), and a recent weight loss of approximately 3 kg. A chest X-ray was obtained on admission which revealed patchy perihilar infiltrates and bronchial wall thickening with moderate bilateral bronchiectasis. The admission BUN and SCR values were 9 and 0.84 mg/dL, respectively. The sputum culture obtained on 10/17 grew few mucoid P. aeruginosa and rare methicillin-resistant Staphylococcus aureus. She was treated with vancomycin 532 mg IV every 6 h, rifampin 600 mg per os (PO) once daily, piperacillin/tazobactam 3.375 g IV every 6 h, and tobramycin 660 mg IV every 24 h (10 mg/kg/dose), all of which were started on day 2.
2 of admission (10/18). Tobramycin serum levels that were collected after the first dose on 10/18 indicated that the 2- and 10-h levels were 27.8 and 2.7 mg/L, respectively, translating to an elevated peak and AUC (Table 1). Because the levels were significantly different compared with the patient’s historical serum concentrations, the dose was continued and the levels were repeated the following day under the assumption that an error had occurred. The repeat 2-h level on 10/19 was again noted to be elevated at 41.7 mg/L. However, prior to collection of the 10-h post-dose level, the analyzer error was discovered and corrected. Therefore, the dose was not adjusted, and the levels were repeated following the 10/20 dose, which revealed the 2- and 10-h levels of 20.6 and 2.4 mg/L, respectively, yielding an extrapolated peak and AUC that were within the target range (Table 1). The patient was continued on this dose for the remainder of her hospital stay. She demonstrated improvement in pulmonary function and no signs/symptoms of aminoglycoside toxicity and was discharged to home after completing her antibiotic course.

Case 2
Patient 2 was a 19-year-old 56.5-kg male admitted on 10/18. He presented with increased cough and sputum production and decreased PFTs for the past month. A chest X-ray was obtained on admission which revealed increased mucus plugging and coarse lung markings that were most prominent in the right upper lobe. The admission BUN and SCr values were 9 and 0.81 mg/dL, respectively. The most recent sputum culture from 10/10 grew three strains of few P. aeruginosa. He was treated with ceftazidime 2 g IV every 8 h and tobramycin 450 mg (10 mg/kg/dose) IV every 24 h. Tobramycin serum concentrations that were collected after the first dose on 10/19 indicated that the 2-h level was 28.1 mg/L (Table 1). However, the analyzer error was discovered and corrected prior to collection of the 10-h post-dose level. Therefore, because of the analyzer error and because the levels were extremely dissimilar to the patient’s historical serum concentrations, despite use of a potentially sub-therapeutic dose (based on historical dose/level data), the dose was not adjusted and the levels were repeated. The repeat levels following the 10/20 dose revealed the 2- and 10-h levels of 14.3 and 1.3 mg/L, respectively, yielding an extrapolated peak and AUC that were sub-therapeutic. After one additional dose adjustment, the dose was ultimately increased 10%, resulting in the 2- and 10-h level of 19.4 and 1.4 mg/L, respectively, levels that were deemed to be therapeutic. The patient was continued on this dose for the remainder of his hospital stay. He demonstrated improvement in pulmonary function and no signs/symptoms of aminoglycoside toxicity and was discharged to home after completing his antibiotic course.

Case 3
Patient 3 was a 26-year-old 45-kg male admitted on 10/19. He presented with shortness of breath upon minimal exertion, increased cough and sputum production, and decreased PFTs. A chest X-ray was obtained on admission which revealed moderate hyperexpansion with prominent bronchovascular markings and bronchiectasis that was most severe in the upper lung fields. The admission BUN and SCr values were 11 and 0.49 mg/dL, respectively. Hemoglobin A1C was 6.3% and urine was negative for microalbumin. The sputum culture obtained on 10/23 grew moderate P. aeruginosa and moderate Stenotrophomonas maltophilia. He was treated with cefepime 2 g IV every 8 h and tobramycin 450 mg (10 mg/kg/dose) IV every 24 h. Tobramycin serum concentrations that were collected after the first dose on 10/19 indicated that the 2-h level was 28.1 mg/L (Table 1). However, the analyzer error was discovered and corrected prior to collection of the 10-h post-dose level. Therefore, because of the analyzer error and because the levels were extremely dissimilar to the patient’s historical serum concentrations, despite use of a potentially sub-therapeutic dose (based on historical dose/level data), the dose was not adjusted and the levels were repeated. The repeat levels following the 10/20 dose revealed the 2- and 10-h levels of 14.3 and 1.3 mg/L, respectively, yielding an extrapolated peak and AUC that were sub-therapeutic. After one additional dose adjustment, the dose was ultimately increased 10%, resulting in the 2- and 10-h level of 19.4 and 1.4 mg/L, respectively, levels that were deemed to be therapeutic. The patient was continued on this dose for the remainder of his hospital stay. He demonstrated improvement in pulmonary function and no signs/symptoms of aminoglycoside toxicity and was discharged to home after completing his antibiotic course.

Discussion
Each patient described in this case series had supra-therapeutic tobramycin serum concentrations reported by the laboratory, despite receiving a tobramycin dose that was individualized using historical therapeutic drug monitoring data. Based on a superficial assessment of these levels, a dose reduction appeared to be indicated. However, historical therapeutic drug monitoring data from the previous hospitalization, which occurred during the same calendar year, indicated that the tobramycin levels during this hospitalization were drastically different for each patient. This raised questions about the validity of these levels. The health-care team, led by the consulting clinical pharmacist, hypothesized that these levels were inaccurate, and that an outside factor was to be blamed. Scenarios explored included the following: (1) an error made by the pharmacist while preparing the medication, (2) an incorrect dose dispensed by the pharmacist, (3) a medication administration error by the nurse, (4) inaccurate collection and/or incorrect documentation of the timing of
blood samples for tobramycin analysis by the nurse, (5) drug–drug interactions and/or drug–laboratory interactions, and (6) an error in the analysis of tobramycin levels in the laboratory.

We reviewed pharmacy documentation detailing the preparation and distribution of tobramycin that was administered to each patient on the dates of 10/18 and/or 10/19. Upon inspection, it was determined that the tobramycin was accurately prepared and that the correct dose was delivered to the floor. We then reviewed the medication administration record (MAR) and the “therapeutic drug monitoring stickers,” which are used by nursing to document the precise time of the medication dose and collection of levels. Based on review of these documents, it was determined that the nurse administered the correct dose to each patient at the correct time, and that the timing of all blood samples was appropriate. The MAR was further scrutinized to ensure there were no drug–drug or drug–laboratory interactions that may have affected the reported levels. Pharmacokinetic studies conducted in patients with CF have demonstrated that aerosolized tobramycin is systemically absorbed, and as a result can produce measurable serum concentrations.5 In line with these data, a clinically significant change in the tobramycin trough has been reported when inhaled and intravenous tobramycin is administered concurrently.6 And previous case reports have documented the occurrence of falsely elevated serum tobramycin levels in patients receiving both inhaled and intravenous tobramycin due to contamination of finger-prick blood samples by the nebulized drug.7-9 However, because the inhaled antibiotics were discontinued upon admission to the hospital, this can be ruled out as a potential cause. We reviewed the method by which nursing obtained the blood samples because falsely elevated tobramycin levels have been reported when blood is collected from a central venous access device rather than from peripheral venipuncture.10,11 This was ruled out as a potential cause because the blood samples were drawn via peripheral venipuncture which aligns with our CF center’s policy. The final potential cause for the discrepant levels on our differential was that an error occurred during the analysis of blood samples in the laboratory. We contacted the laboratory to discuss the cases, and after completion of research by laboratory personnel, it was determined that despite established quality control policies and procedures to ensure accurate data reporting within the laboratory, an analyzer error had occurred that resulted in the reporting of the erroneously high serum levels. It remains unclear whether the erroneous concentrations obtained from the malfunctioning analyzer occurred as a consequence of instrument calibration drift or a gross instrument error. Nevertheless, once the laboratory’s tobramycin analyzer was recalibrated, the reported levels were comparable to historical levels.

Failing to adjust tobramycin dosing based on an elevated 18-h level, trough, or AUC increases the risk for toxicity.12 Therefore, upon encountering high serum levels, the dose is typically reduced. However, reducing a dose when it is actually therapeutic may place the patient at risk for treatment failure in the short term and increase the risk for developing resistant bacterial species in the lung over time. Based on the initial set of levels, to achieve a target AUC of approximately 100 mg·h/L, patients 1, 2, and 3 would have required a 52% reduction to 316 mg (4.8 mg/kg/dose), 40% reduction to 335 mg (5.9 mg/kg/dose), and a 27% reduction to 329 mg (7.3 mg/kg/dose), respectively. If the dose would have been reduced to this extent, both the peak serum concentration and the AUC would have been significantly below targets. To ensure safe and effective treatment, it is therefore essential to consider the entire clinical picture while engaging in therapeutic drug monitoring and not simply react to numbers reported by the laboratory.

Clinicians rely on accurate laboratory results to provide optimal patient care. They therefore typically trust what is reported by the laboratory to be accurate. However, the accuracy of these levels can be dependent on the laboratory’s quality control policies and procedures, the analyzer used within the laboratory, and the experience of the laboratory personnel. Even with experienced personnel, reliable equipment, and established quality control, reporting errors may still occur and go unnoticed until after patient care decisions based on these laboratory data are made. In this case, the laboratory performed a root-cause analysis, determined that the equipment used to analyze tobramycin levels was outdated, and subsequently purchased a new analyzer.

In summary, this case series emphasizes the clinical importance of critically analyzing reported levels, and specifically the importance of utilizing past therapeutic drug monitoring data, if available, for all patients treated with intravenous tobramycin. If a patient was therapeutic on a similar dose of tobramycin during a previous admission, a dose adjustment may not be necessary, and clinicians should consider repeating levels while pursuing alternative explanations for the discrepant serum levels.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
1. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802–808.
2. Prescott WA. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262–269.
3. Prescott WA and Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy 2010; 30: 95–108.
4. Chuck SK, Raber SR, Rodvold KA, et al. National survey of extended-interval aminoglycoside dosing. *Clin Infect Dis* 2000; 30: 433–439.

5. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. *Chest* 2002; 122: 219–226.

6. Stenbit AE, Bullington WM, Heh JL, et al. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. *J Cyst Fibros* 2013; 12: 403–406.

7. Elidemir O, Maciejewski SR and Oermann CM. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. *Pediatr Pulmonol* 2000; 29: 43–45.

8. Redmann S, Wainwright C, Stacey S, et al. Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulized tobramycin (TOBI): a short report. *Ther Drug Monit* 2005; 27: 205–207.

9. Struthers SL, Nicholson T, Jones G, et al. Falsely elevated serum tobraycin levels in a patient receiving nebulised tobramycin. *J Cystic Fibros* 2002; 1: 146–147.

10. Boodhan S, Maloney AM and Dupuis LL. Extent of agreement in gentamicin concentration between serum that is drawn peripherally and from central venous catheters. *Pediatrics* 2006; 118: e1650–e1656.

11. Mogayzel PJ Jr, McNeil A, McMahan S, et al. Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent. *Pediatr Nurs* 2008; 34: 464–469.

12. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother* 1999; 43: 1549–1555.